Growth Metrics

Boston Scientific (BSX) Equity Average (2016 - 2025)

Boston Scientific (BSX) has disclosed Equity Average for 16 consecutive years, with $23.9 billion as the latest value for Q4 2025.

  • Quarterly Equity Average rose 12.07% to $23.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.9 billion through Dec 2025, up 12.07% year-over-year, with the annual reading at $23.2 billion for FY2025, 11.9% up from the prior year.
  • Equity Average hit $23.9 billion in Q4 2025 for Boston Scientific, up from $11.7 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $23.9 billion in Q4 2025 to a low of -$1.1 billion in Q1 2023.
  • Historically, Equity Average has averaged $10.0 billion across 5 years, with a median of $9.5 billion in 2022.
  • Biggest YoY gain for Equity Average was 982.05% in 2024; the steepest drop was 904.65% in 2024.
  • Year by year, Equity Average stood at $18.2 billion in 2021, then tumbled by 57.78% to $7.7 billion in 2022, then skyrocketed by 149.63% to $19.2 billion in 2023, then rose by 11.18% to $21.4 billion in 2024, then rose by 12.07% to $23.9 billion in 2025.
  • Business Quant data shows Equity Average for BSX at $23.9 billion in Q4 2025, $11.7 billion in Q3 2025, and $1.7 billion in Q2 2025.